Literature DB >> 31999814

The one-two punch (of CAR T cells).

Nirali N Shah1.   

Abstract

Mesh：

Substances：

Year:  2020        PMID： 31999814      PMCID： PMC6993015          DOI： 10.1182/blood.2019004272

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  10 in total

1.  Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults.

Authors:  Rebecca A Gardner; Olivia Finney; Colleen Annesley; Hannah Brakke; Corinne Summers; Kasey Leger; Marie Bleakley; Christopher Brown; Stephanie Mgebroff; Karen S Kelly-Spratt; Virginia Hoglund; Catherine Lindgren; Assaf P Oron; Daniel Li; Stanley R Riddell; Julie R Park; Michael C Jensen
Journal:  Blood       Date:  2017-04-13       Impact factor: 22.113

Review 2.  A 50-year journey to cure childhood acute lymphoblastic leukemia.

Authors:  Ching-Hon Pui; William E Evans
Journal:  Semin Hematol       Date:  2013-07       Impact factor: 3.851

3.  High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients.

Authors:  J Pan; J F Yang; B P Deng; X J Zhao; X Zhang; Y H Lin; Y N Wu; Z L Deng; Y L Zhang; S H Liu; T Wu; P H Lu; D P Lu; A H Chang; C R Tong
Journal:  Leukemia       Date:  2017-05-15       Impact factor: 11.528

4.  Sequential CD19-22 CAR T therapy induces sustained remission in children with r/r B-ALL.

Authors:  Jing Pan; Shiyu Zuo; Biping Deng; Xiuwen Xu; Chuo Li; Qinlong Zheng; Zhuojun Ling; Weiliang Song; Jinlong Xu; Jiajia Duan; Zelin Wang; Xinjian Yu; Alex H Chang; Xiaoming Feng; Chunrong Tong
Journal:  Blood       Date:  2020-01-30       Impact factor: 22.113

5.  Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies.

Authors:  Marco Ruella; David M Barrett; Saad S Kenderian; Olga Shestova; Ted J Hofmann; Jessica Perazzelli; Michael Klichinsky; Vania Aikawa; Farzana Nazimuddin; Miroslaw Kozlowski; John Scholler; Simon F Lacey; Jan J Melenhorst; Jennifer J D Morrissette; David A Christian; Christopher A Hunter; Michael Kalos; David L Porter; Carl H June; Stephan A Grupp; Saar Gill
Journal:  J Clin Invest       Date:  2016-08-29       Impact factor: 14.808

6.  Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.

Authors:  Shannon L Maude; Theodore W Laetsch; Jochen Buechner; Susana Rives; Michael Boyer; Henrique Bittencourt; Peter Bader; Michael R Verneris; Heather E Stefanski; Gary D Myers; Muna Qayed; Barbara De Moerloose; Hidefumi Hiramatsu; Krysta Schlis; Kara L Davis; Paul L Martin; Eneida R Nemecek; Gregory A Yanik; Christina Peters; Andre Baruchel; Nicolas Boissel; Francoise Mechinaud; Adriana Balduzzi; Joerg Krueger; Carl H June; Bruce L Levine; Patricia Wood; Tetiana Taran; Mimi Leung; Karen T Mueller; Yiyun Zhang; Kapildeb Sen; David Lebwohl; Michael A Pulsipher; Stephan A Grupp
Journal:  N Engl J Med       Date:  2018-02-01       Impact factor: 91.245

7.  CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia.

Authors:  Jing Pan; Qing Niu; Alex H Chang; Xiaoming Feng; Chunrong Tong; Biping Deng; Shuangyou Liu; Tong Wu; Zhiyong Gao; Zhaoli Liu; Yue Zhang; Xiaomin Qu; Yanlei Zhang; Shaohui Liu; Zhuojun Ling; Yuehui Lin; Yongqiang Zhao; Yanzhi Song; Xiyou Tan; Yan Zhang; Zhihui Li; Zhichao Yin; Bingzhen Chen; Xinjian Yu; Ju Yan; Qinlong Zheng; Xuan Zhou; Jin Gao
Journal:  Leukemia       Date:  2019-05-20       Impact factor: 11.528

8.  Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22.

Authors:  Haiying Qin; Sneha Ramakrishna; Sang Nguyen; Thomas J Fountaine; Anusha Ponduri; Maryalice Stetler-Stevenson; Constance M Yuan; Waleed Haso; Jack F Shern; Nirali N Shah; Terry J Fry
Journal:  Mol Ther Oncolytics       Date:  2018-11-06       Impact factor: 7.200

9.  A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.

Authors:  Dina Schneider; Ying Xiong; Darong Wu; Volker Nӧlle; Sarah Schmitz; Waleed Haso; Andrew Kaiser; Boro Dropulic; Rimas J Orentas
Journal:  J Immunother Cancer       Date:  2017-05-16       Impact factor: 13.751

10.  CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.

Authors:  Terry J Fry; Nirali N Shah; Rimas J Orentas; Maryalice Stetler-Stevenson; Constance M Yuan; Sneha Ramakrishna; Pamela Wolters; Staci Martin; Cindy Delbrook; Bonnie Yates; Haneen Shalabi; Thomas J Fountaine; Jack F Shern; Robbie G Majzner; David F Stroncek; Marianna Sabatino; Yang Feng; Dimiter S Dimitrov; Ling Zhang; Sang Nguyen; Haiying Qin; Boro Dropulic; Daniel W Lee; Crystal L Mackall
Journal:  Nat Med       Date:  2017-11-20       Impact factor: 53.440
  10 in total
  2 in total

Review 1.  In Like a Lamb; Out Like a Lion: Marching CAR T Cells Toward Enhanced Efficacy in B-ALL.

Authors:  Pouya Safarzadeh Kozani; Pooria Safarzadeh Kozani; Roddy S O'Connor
Journal:  Mol Cancer Ther       Date:  2021-04-26       Impact factor: 6.009

Review 2.  Challenges and Clinical Strategies of CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Overview and Developments.

Authors:  Xinjie Xu; Shengkang Huang; Xinyi Xiao; Qihang Sun; Xiaoqian Liang; Sifei Chen; Zijing Zhao; Zhaochang Huo; Sanfang Tu; Yuhua Li
Journal:  Front Immunol       Date:  2021-02-10       Impact factor: 7.561
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.